Skip to content

A Comparison psycho-sexual therapy and pharmacotherapy Bupropion interventions on improvement of sexual function in infertile women

A Comparison of the effect psycho-sexual therapy and pharmacotherapy Bupropion interventions on improvement of sexual function in infertile women

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2015042721955N2
Enrollment
99
Registered
2015-08-02
Start date
2015-01-01
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sexual Dysfunction. Sexual dysfunction, not caused by organic disorder or disease

Interventions

Intervention 1: Psycho-sexual therapy group: This group will participate in a two-hour group session for 10 weeks. Each group consists of 8–12 members. Therapeutic model is a combination of mind fulln
Treatment - Other
Treatment - Drugs
Psycho-sexual therapy group: This group will participate in a two-hour group session for 10 weeks. Each group consists of 8–12 members. Therapeutic model is a combination of mind fullness-Based cognit
Pharmacotherapy group: This group will take a tablet of Bupropion SR (150 mg) daily (evening) (manufactured by D Abidi plant) for two months by a psychiatrist. Subjects will receive 30 tablets after t
Control group: Participants in this group will complete questionnaires at the beginning of the study and two months afterward. In order to observe the ethics of research, members of this group will be

Sponsors

Babol University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
15 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria included: The less or equal score of 26.55 from Female Sexual Function Index(FSFI); The final diagnosis with clinical interview is based on DSM-V criteria by psychologist; duration of infertility more than 1 year; women infertile who did not decide to undergo fertility treatment until 2 months afterward; aged between 15-45 years; ability to read and to write; having a stable sexual activity(at least for recent four weeks); availability of the husband; no remarrying of couples; no history of sterilization; no foster child. Exclusion criteria included: drug abuse; severe psychiatric disorders(major depression, bipolar disorder, patients with suicidal idea or psychosis); history of physical illness(diabetes mellitus, cardiovascular diseases, hypertension, hyperthyroidism, hypothyroidism, epilepsy, hepatic dysfunction); physical problems(spinal cord injury, limb deformity); mental health problems under the treatment of a physician; drugs consumers causing sexual dysfunction such as barbiturates, benzodiazepines , antidepressants, ant hypertensions; having psychological support( psychotherapy sessions, relaxation techniques, yoga ); experiencing a stressful event in the past three months(death or serious illness in the family, a major change in living conditions).

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Sexual function. Timepoint: Before and two months after of intervention. Method of measurement: Female Sexual Function Index (FSFI), and clinical interview based on the diagnostic criteria of DSM-V.

Secondary

MeasureTime frame
Depression, Anxiety, General health, Sleep Quality, Couple Burnout, Body Image. Timepoint: Before and two months after of intervention. Method of measurement: Beck Depression Inventory (BDI), Spielberger State-Trait Anxiety Inventory (STAI), General health questionnaire (GHQ), Pittsburgh Sleep Quality Index (PSQI), Couple Burnout Measurement (CBM), and Body Image Assessment, and clinical interview based on the diagnostic criteria of DSM-V.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHajar Pasha

Babol University of Medical Sciences

h.pasha@mubabol.ac.ir; pashahajar@yahoo.com; dhajarpasha@gmail.com+98 11 3219 0597

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 24, 2026